In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Use of televisits in studies and related PV concerns
As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes. As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
Virtual Congresses – Facing up to virtual reality
The COVID-19 pandemic has challenged the traditional onsite congress engagement experience and forced pharma to rethink face to face events.
-
Going through changes
ICON's Angela Brown considers what manufacturers can learn from medical device regulation (MDR) and the effect it will have on the in vitro diagnostic landscape (IVD)
-
Challenges and opportunities in harnessing the potential of circulating tumor cells
Scientific Affairs Manager Candice Willey provides commentary on the difficulties of using CTCs in diagnostic testing despite their promise, the emergence of new CTC technologies to improve tumor sample accessibility, and the benefits of integrating CTC information into clinical trial decisions.
-
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19 by adopting patient-centric technologies to keep patients safe and studies on track. The article is published in PharmaFile Spring 2020 on page 40.
-
Here’s what we have to do to show a coronavirus vaccine works
A article featuring expert commentary from ICON's Cynthia Dukes about the development of a vaccine for COVID-19.
-
Improving access and reimbursement for specialty therapies
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, payers are scrutinising the economic value more closely. ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
-
Women in healthcare: Dr. Nuala Murphy
Pharma Times interviews Dr. Nuala Murphy, ICON's President of Clinical Research Services.
